CTI BioPharma
CTI BioPharma
Explore linked clinical trials.2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms | Hemic and Lymphatic Diseases, T-cell and NK-cell neoplasm, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoproliferative syndrome | Recruiting | Phase 2 | 2026-01-29 | NCT04858256 | |
| Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis | Active, not recruiting | Phase 2 | 2022-08-22 | NCT03645824 |